Drug Profile

Glycoprotein therapeutic - Nanomix Corporation

Alternative Names: Ipoxyn

Latest Information Update: 17 May 2023

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Boston Therapeutics
Developer Nanomix Corporation
Class Glycoproteins
Mechanism of Action Oxygen carriers

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity Yes
Available For Licensing Yes

Highest Development Phases

Suspended Anaemia; Cardiovascular disorders; Peripheral ischaemia

Most Recent Events

07 Jun 2017 Boston Therapeutics is seeking partners for funding the development of glycoprotein therapeutic as of 28 Mar 2017 .
28 Mar 2017 Suspended - Preclinical for Peripheral ischaemia, Cardiovascular disorders and Anaemia in USA until Boston Therapeutics can secure funds for the compound (IV)
30 May 2014 Preclinical development is ongoing

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com